ESTRO 2024 - Abstract Book

S1042

Clinical - Gynaecology

ESTRO 2024

patterns for LACC patients in a tertiary cancer center. The study explores the impact of dose escalation on the high-risk clinical target volume (HR CTV) and its effect on local control and survival.

Material/Methods:

Data from LACC patients treated between 2017 and 2021 was collected and reviewed. Eligible patients underwent staging with MRI and PETCT and received curative intent CCRT and IGABT, involving 45Gy-50.4 Gy/25-28 fractions of EBRT followed by 3-4 fractions of intracavitary BT at 7Gy/fraction. Daily image-guided radiotherapy (IGRT) and MRI-based IGABT were utilized, with involved nodes boosted sequentially or using a Simulated Integrated Boost (SIB) technique. Follow-up involved clinical examination and a 3-month post-treatment MRI.

Diagram 1 – Patterns of lymph node disease at time of diagnosis (left) and at time of nodal failure (right)

Results:

A total of 70 eligible patients were included in the analysis. The mean age was 51 and the mean treatment duration was 46.88 days (sd±4.78, range 36-61). At a mean follow-up time of 58 months, 14 (20%) patients had recurred, with a mean time to recurrence of 21.3 months. The 5 year overall survival for LACC patients in our cohort is 69%.

Patient Characteristics

Age, mean ± Sd (min-max)

51.04±12.80 (28-82)

Pathology

SCC

58 (82.9%)

Adenosquamous

1(1.4 %)

Adeno

10(14.3 %)

Rhabdomyosarcoma

1(1.4 %)

FIGO staging

1B2 = 2 (2.8%)

2A = 8 (11.3%)

3A = 1 (1.4%)

4A = 1 (1.4%)

1B1 = 1 (1.4%)

2B = 24 (34.3%)

3B = 2 (2.8%)

3C = 8 (11.4%)

Sites of Disease Recurrence (14/70 patients = 20%)

Distant disease = 5 (7.1%)

Pelvic lymph node = 3 (4.3%)

Locoregional/cervix = 1 (1.4%)

Multiple = 5 (7.1%)